Skip to main content

Peer Review reports

From: Safety and tolerability of erenumab in individuals with episodic or chronic migraine across age groups: a pooled analysis of placebo-controlled trials

Original Submission
22 Jun 2022 Submitted Original manuscript
10 Jul 2022 Reviewed Reviewer Report - Francesca Pistoia
10 Jul 2022 Reviewed Reviewer Report
22 Jul 2022 Author responded Author comments - Christian Lampl
Resubmission - Version 2
22 Jul 2022 Submitted Manuscript version 2
23 Jul 2022 Editorially accepted
18 Aug 2022 Article published 10.1186/s10194-022-01470-4

You can find further information about peer review here.

Back to article page